Related Experiment Video
Updated: Apr 18, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis
Lijuan Chen1,2, Jie Liu1,2, Junfeng Lu1,2
1Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Objective:
To evaluate the optimal first-line treatment options for programmed death-ligand 1 (PD-L1) negative lung adenocarcinoma (LUAD) patients without common gene-alterations.
Methods:
A total of 159 PD-L1-negative LUAD patients without common gene-alterations were included. Chemotherapy was administered in 44 cases (group A), immunotherapy-chemotherapy combinations in 55 cases (group B) and bevacizumab plus chemotherapy in 60 patients (group C). A head-to-head comparison of the clinical effectiveness and safety for these standard treatment regimens was conducted.
Results:
The median follow-up time was 30.9 months. For the entire cohort, median PFS was 6.67 months [95% CI 5.83-7.51], and median OS was 15.83 months [95% CI 13.46-18.21]. OS was significantly longer in group C versus others (C vs B median 21.6 months [95% CI 17.78-25.42] vs 12.63 months [95% CI 8.14-17.13]; HR 0.59 [95% CI 0.39-0.9], P = 0.01; C vs A median 21.6 months [95% CI 17.78-25.42] vs 13.47 months [95% CI 9.68-17.26], HR 0.47 [95% CI 0.3-0.71], P= 0.001), but no substantial difference was noted between group A and B (HR 0.78 [95% CI 0.51-1.2], P= 0.26). For PFS in pairwise comparison, group B and C were statistically superior to group A (B vs A median 5.6 months [95% CI 4.56-6.64] vs 5.17 months [95% CI 4.09-6.25]; hazard ratio (HR) 0.56 [95% CI 0.37-0.87], P = 0.009; C vs A median 8.57 months [95% CI 7.47-9.66] vs 5.17 months [95% CI 4.09-6.25]; HR 0.43 [95% CI 0.28-0.7], P< 0.001), whereas no significant difference was found between group B and C (HR 0.76 [95% CI 0.51-1.11], P= 0.16). The disease control rate (DCR) improvement was sustained with group C (A vs B vs C: 84.09% vs 83.64% vs 96.67%, respectively (P<0.05)). Multivariate analysis showed that the performance status score and treatment regimen were factors influencing PFS as well as OS. The treatment-emergent adverse events (AEs) of grade 3-4 occurred in a similar proportion of patients in each group (P>0.05), and all AEs were manageable without fatal toxicities.
Conclusions:
Bevacizumab plus chemotherapy should be prioritized in PD-L1-negative LUAD patients without common driver gene alterations. These findings may facilitate individualized treatment options.
Insights
For lung adenocarcinoma patients negative for programmed death-ligand 1 (PD-L1) and common gene alterations, bevacizumab plus chemotherapy offers superior overall survival and disease control compared to chemotherapy alone or with immunotherapy.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Lung adenocarcinoma (LUAD) treatment for patients negative for programmed death-ligand 1 (PD-L1) and common gene alterations remains a challenge.
- Identifying optimal first-line therapies is crucial for improving patient outcomes in this specific LUAD subgroup.
Purpose of the Study:
- To evaluate and compare the clinical effectiveness and safety of different first-line treatment regimens for PD-L1-negative LUAD patients lacking common gene alterations.
- To determine the optimal treatment strategy for this patient population.
Main Methods:
- A comparative study included 159 PD-L1-negative LUAD patients without common gene alterations.
- Patients received either chemotherapy (Group A), immunotherapy-chemotherapy (Group B), or bevacizumab plus chemotherapy (Group C).
- Clinical effectiveness (PFS, OS, DCR) and safety (AEs) were analyzed.
Main Results:
- Bevacizumab plus chemotherapy (Group C) demonstrated significantly longer overall survival (OS) compared to chemotherapy alone (Group A) and immunotherapy-chemotherapy (Group B).
- Progression-free survival (PFS) was significantly improved in Groups B and C compared to Group A.
- Group C showed a superior disease control rate (DCR), with manageable grade 3-4 adverse events comparable across all groups.
Conclusions:
- Bevacizumab plus chemotherapy is recommended as a prioritized first-line treatment for PD-L1-negative LUAD patients without common driver gene alterations.
- This regimen offers improved survival benefits and disease control, supporting individualized treatment strategies.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...